Snowtorious Krypton Enters the Polish Medical Cannabis Market

Polish patients will soon gain access to a new medical cannabis strain from Canopy Growth. On January 30, 2026, pharmacies across Poland will introduce Snowtorious Krypton, a high-potency product from Spectrum Therapeutics. This strain is designed for patients who rely on strong therapeutic effects and value traditional cultivation and preparation methods.

High-Potency Indica Hybrid, Snowtorious, from Canopy Growth Launches January 30th, 2026

Snowtorious Krypton is an indica-dominant hybrid created through a deliberate cross of two respected genetic lines: Krypton and Kush Mints. Its genetic backbone is based on the well-known 91 Krypt lineage. By combining these varieties, the producer aimed to achieve both genetic stability and a consistent morphological profile, while delivering balanced and reliable effects suited for medical use.

The product is registered under permit number 30103 and features a clearly defined cannabinoid profile. Labels indicate a THC range between 22% and 27%, with an average of approximately 25%. CBD content remains below 0.5%. This elevated THC level positions Snowtorious Krypton as a strong option for patients requiring intensive therapeutic support rather than mild or introductory formulations.

Visually, the Snowtorious strain lives up to its name. The dense flowers are heavily coated with trichomes, giving them a frosted, snow-like appearance. Deep green buds are contrasted by vivid orange pistils, creating a striking and easily recognizable look. This visual quality reflects the careful cultivation practices used throughout production.

The aroma and scent profile of Snowtorious Krypton is shaped by three dominant terpenes: myrcene, limonene, and caryophyllene. Together, they produce a complex sensory experience marked by earthy and musky undertones, a pronounced fuel-like note often associated with diesel aromas, and a distinctive fermented accent that can resemble the sharp intensity of aged cheese.

Canopy Growth has emphasized artisanal quality in the finishing process. The plants are hang-dried, allowing moisture to escape slowly and helping preserve the full terpene spectrum. Each flower is also hand-trimmed, a method that maintains the natural structure of the buds and minimizes the loss of trichomes that can occur during machine processing.

Snowtorious Krypton will be available in pharmacies in 5-gram packages of dried flower. Its official market debut is scheduled for the last Friday of January 2026, expanding the range of high-THC medical cannabis options available to Polish patients.

__

(Featured image by Leon Kohle via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.